Objective To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S. Methods We used publicly available data from the U.S. Vaccine Adverse Event Reporting System (VAERS) collected between January 1, 2021 and June 14, 2021. All free text symptoms that were reported within 42 days of vaccine administration were manually reviewed and grouped into 36 individual neurological diagnostic categories. Post‐vaccination neurological event rates were compared between vaccine types and to age‐matched baseline incidence rates in the U.S. and rates of neurological events following COVID. Results Of 306,907,697 COVID vaccine doses administered during the study timeframe, 314,610 (0.1%) people reported any adverse event and 105,214 (0.03%) reported neurological adverse events in a median of 1 day (IQR0‐3) from inoculation. Guillain‐Barre Syndrome (GBS), and cerebral venous thrombosis (CVT) occurred in fewer than 1 per 1,000,000 doses. Significantly more neurological adverse events were reported following Janssen (Ad26.COV2.S) vaccination compared to either Pfizer‐BioNtech (BNT162b2) or Moderna (mRNA‐1,273; 0.15% vs 0.03% vs 0.03% of doses, respectively, p < 0.0001). The observed‐to‐expected ratios for GBS, CVT and seizure following Janssen vaccination were ≥1.5‐fold higher than background rates. However, the rate of neurological events after acute SARS‐CoV‐2 infection was up to 617‐fold higher than after COVID vaccination. Interpretation Reports of serious neurological events following COVID vaccination are rare. GBS, CVT and seizure may occur at higher than background rates following Janssen vaccination. Despite this, rates of neurological complications following acute SARS‐CoV‐2 infection are up to 617‐fold higher than after COVID vaccination. ANN NEUROL 2022;91:756–771

No abstract

Our study highlights the spectrum of SMDs and the lack of correlation between types of SMDs and underlying etiologies. Preventable causes such as infections, HYP, trauma, and kernicterus still play a major role in pathogenesis of SMD.

• Structural changes in early multiple system atrophy were evaluated using multi-modal neuroimaging. • White matter was more affected than grey matter in early MSA. • Clinical variables did not correlate with early structural changes.

Background: Psychogenic movement disorders (PMD) is a group of disorders that cannot be attributed to any structural or biochemical abnormality, but has an underlying psychiatric illness. The profile of PMD varies according to country and socioeconomic factors. Methods: The present study reports the clinical profile of patients with PMD from India. Seventy-three patients with documented or clinically established PMD were seen over a period of 14 years with detailed neurological and psychiatric examinations. Results: The mean age at presentation was 29.1 ± 15.1 years (women, 51%). Approximately 30% were ≤18 years of age (boys, 63.6%). The onset of symptoms was abrupt in 61.6% and the initial body part most often affected was right upper limb (adults, 29.4%; children, 31.8%). Tremor was observed in 31.4% of adults and 9% of children, whereas myoclonus was more common in children (36.4%). Tremors were more often seen in women (42.3%) than in men (20%), whereas myoclonus was almost equally prevalent in girls (37.5%) and boys (35.7%). Depression was the most common psychiatric comorbidity (men, 16%; women, 15.4%). About 42.5% required hospital admission and 57.5% had significant reduction or complete cessation of PMD after counseling, antidepressants, and/ or placebo. Conclusions: PMD was equally prevalent among women and men. Tremor was most often observed in adults, whereas myoclonus was most often observed in children. Electrophysiology and placebo were useful supplementary tools for diagnosing PMD.RÉSUMÉ: Déterminants des sujets présentant des troubles psychogènes du mouvement selon le sexe et l'âge: profil clinique de 73 patients. Contexte: Les troubles psychogènes du mouvement (TPM) constituent un groupe de problèmes de santé qui ne peuvent être attribués à aucune anomalie structurale ou biochimique et qui sont dus à une maladie psychiatrique sous-jacente. Le profil des TPM varie selon le pays et les facteurs socio-économiques des patients. Méthode: Nous rapportons le profil de patients présentant des TPM en Inde. Soixante-treize patients présentant des TPM documentés ou établis cliniquement ont subi des examens neurologiques et psychiatriques détaillés au cours d'une période de 14 ans. Résultats: L'âge moyen des patients au moment de la consultation initiale était de 29,1 ± 15.1 ans et 51% étaient des femmes. À peu près 30% étaient âgés de 18 ans ou moins et parmi eux, 63,6% étaient des garçons. Le début des symptômes avait été soudain chez 61,6% et la partie du corps initialement touchée était le plus souvent le membre supérieur droit (29,4% chez les adultes, 31,8% chez les enfants). Chez les adultes, 31,4% avaient du tremblement ainsi que 9% des enfants. La myoclonie était plus fréquente chez les enfants (36,4%). Les tremblements étaient plus fréquemment observés chez les femmes (42,3%) que chez les hommes (20%). La myoclonie était presqu'aussi fréquente chez les filles (37,5%) que chez les garçons (35,7%). La dépression était la comorbidité psychiatrique la plus fréquente tant chez les hommes (16%...